Avalyn Pharma Financial Statements
NASDAQ: AVLNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
25.76+0.04 (+0.16%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Avalyn Pharma has no annual income statement on file yet, so quarterly figures are shown instead.
Avalyn Pharma revenue and earnings
Avalyn Pharma reported a net loss of $28.9 million. Diluted earnings per share came in at -$0.98.
Summary generated from market data by MetaCap's automated system. Methodology
Avalyn Pharma income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Operating Expenses | 31.29M | 27.91M | 21.78M | 18.72M |
| Research & Development | 24.73M | 22.89M | 17.88M | 15.32M |
| Operating Income | -31.29M | -27.91M | -21.78M | -18.72M |
| Interest Expense | 272.00K | 98.00K | 0 | 0 |
| Other Income (Expense) | 2.35M | 1.04M | 1.59M | 1.21M |
| Income Tax | 0 | 0 | 0 | 0 |
| Net Income | -28.93M | -26.87M | -20.19M | -17.50M |
| Net Income growth (YoY) | — | — | — | — |
| EPS (Basic) | -0.98 | -21.83 | -17.63 | -63.24 |
| EPS (Diluted) | -0.98 | -21.83 | -17.63 | -63.24 |
| Shares Outstanding (Basic) | 29.65M | 1.23M | 1.15M | 276.79K |
| Shares Outstanding (Diluted) | 29.65M | 1.23M | 1.15M | 276.79K |
| EBITDA | -31.18M | -27.85M | -21.77M | -18.71M |
This table shows 4 quarterly periods of Avalyn Pharma's income statement, from Q2 2026 back to Q? 2025, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow AVLN's reporting calendar. What is a income statement?